Non-squamous Nonsmall Cell Neoplasm of Lung Clinical Trial
Official title:
Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM
Cisplatin and pemetrexed combination or carboplatin, paclitaxel and bevacizumab are now considered as standard treatment in non-squamous cell lung carcinoma (NSCLC). Both main registrative trials are considered positive because they reached their objectives, but within them, the Quality of Life (QoL) of patients was not detailed neither has represented as primary objective of the studies. It is considered that, together with enhancements that are added to the knowledge of the biology of NSCLC, QoL may influence the therapeutic choice if one of the associations show to be better tolerated by the patient and favours an amelioration of his QoL.
The study aims primarily to verify the null hypothesis that between the two schemes under
consideration there is no minimal interesting difference (MID) (i.e. a difference of
clinical interest) after initial 3 months of maintenance.EuroQ5D (EQ5D) questionnaire total
score and EQ5D visual analog scale (VAS)are validated and very simple to be administered.The
statistical hypothesis tests described above are performed with t-test for unpaired data (or
equivalent non-parametric, pending verification of normality of distribution by Shapiro-Wilk
test), with alpha error = 0.05 (2-sided). It is assumed that:
1. about 20% of randomized patients experienced a progression of disease before the time
of evaluation of the primary endpoint, and that
2. this eventuality was not significantly different between the two treatments. The total
sample to be enrolled for this study will then be increased to 118 patients [(49 +49)
+20%)]
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment